TY - JOUR
T1 - Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia
AU - Apostolidou, Efrosyni
AU - Estey, Elihu
AU - Cortes, Jorge
AU - Garcia-Manero, Guillermo
AU - Faderl, Stefan
AU - Thomas, Deborah
AU - Tsimberidou, Apostolia
AU - Kantarjian, Hagop
AU - Giles, Francis J.
PY - 2003/4/1
Y1 - 2003/4/1
N2 - In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.
AB - In a recent phase I study, a combination of gemcitabine at 10mg/(m2min) for 12h and mitoxantrone 12mg/m2 daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refractory acute myeloid leukemia (AML). In a cohort of 18 patients with very refractory disease (6 primary refractory, 12 relapsed, mean initial CR duration 3.5 months), one patient achieved a CR, a second CR with incomplete platelet recovery (CRp). Sepsis and mucositis were significant extramedullary toxicities. The gemcitabine and mitoxantrone regimen was feasible to administer even in heavily pre-treated patients. It was not active in patients who had failed a prior salvage regimen. It may warrant further study in patients with primary resistant AML.
KW - Gemcitabine infusion
KW - Mitoxantrone
KW - Refractory myeloid leukemia
UR - https://www.scopus.com/pages/publications/0037377316
U2 - 10.1016/S0145-2126(02)00171-6
DO - 10.1016/S0145-2126(02)00171-6
M3 - Article
C2 - 12531220
AN - SCOPUS:0037377316
SN - 0145-2126
VL - 27
SP - 301
EP - 304
JO - Leukemia Research
JF - Leukemia Research
IS - 4
ER -
